Previous 10 | Next 10 |
The following slide deck was published by IQVIA Holdings Inc. in conjunction with their 2022 Q4 earnings call. For further details see: IQVIA Holdings Inc. 2022 Q4 - Results - Earnings Call Presentation
IQVIA Holdings (IQV -4.6%) saw its Q4 2021 net income rise 167% compared to the prior-year period, helping the company to beat on the top and bottom lines. GAAP net income in quarter was and GAAP diluted EPS was $1.63. IQVIA (IQV -4.6%) was helped in the quarter by a 10.2% year over year incr...
IQVIA Holdings Inc. (IQV) Q4 2021 Earnings Conference Call February 15, 2022 09:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations & Corporate Communications Ari Bousbib - Chairman & Chief Executive Officer Ron Bruehlman - Executive Vice President &a...
IQVIA press release (NYSE:IQV): Q4 Non-GAAP EPS of $2.55 beats by $0.12. Revenue of $3.64B (+10.3% Y/Y) beats by $30M. For the full year of 2022, Revenue guidance range of $14,700 million to $15,000 million. Adjusted EBITDA to be between $3,330 million and $3,405 million, Adjusted Diluted Ear...
Revenue of $3,636 million for the fourth quarter grew 10.2 percent year-over-year on a reported basis and 11.6 percent at constant currency GAAP Net Income of $318 million for the fourth quarter grew 167.2 percent year-over-year Adjusted EBITDA of $828 million for th...
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...
IQVIA (NYSE:IQV) is scheduled to announce Q4 earnings results on Tuesday, February 15th, before market open. The consensus EPS Estimate is $2.43 (+15.2% Y/Y) and the consensus Revenue Estimate is $3.61B (+9.4% Y/Y). Over the last 2 years, IQV has beaten EPS estimates 100% of the time and has ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 11:00 a.m. ...
Clinical trial activity saw sustained growth through the pandemic with 5,500 new planned clinical trial starts in 2021, a 14% increase over 2020 The total number of products in active development exceeded 6,000, up 68% from 2016 A record 84 novel active substances were initial...
Updating its Tactical U.S. Equity Themes, UBS introduced a new theme of Selloff Opporutunities. The screen "highlights a list of companies that look attractive following recent market volatility." "We believe some stocks have been unfairly punished in the sell-off," UBS' theme team wrote in a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...